PL324091A1 - Compositions and procedure for treating sclerosis multiplex - Google Patents
Compositions and procedure for treating sclerosis multiplexInfo
- Publication number
- PL324091A1 PL324091A1 PL95324091A PL32409195A PL324091A1 PL 324091 A1 PL324091 A1 PL 324091A1 PL 95324091 A PL95324091 A PL 95324091A PL 32409195 A PL32409195 A PL 32409195A PL 324091 A1 PL324091 A1 PL 324091A1
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- procedure
- sclerosis multiplex
- treating sclerosis
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32822494A | 1994-10-25 | 1994-10-25 | |
US40422895A | 1995-03-15 | 1995-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL324091A1 true PL324091A1 (en) | 1998-05-11 |
Family
ID=26986277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL95324091A PL324091A1 (en) | 1994-10-25 | 1995-10-25 | Compositions and procedure for treating sclerosis multiplex |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0787147A1 (en) |
JP (1) | JPH10504039A (en) |
AU (1) | AU4278296A (en) |
BR (1) | BR9509438A (en) |
CA (1) | CA2203629A1 (en) |
CZ (1) | CZ122697A3 (en) |
FI (1) | FI971750A (en) |
HU (1) | HUT77047A (en) |
IL (1) | IL115766A0 (en) |
IS (1) | IS4466A (en) |
NO (1) | NO971900L (en) |
PL (1) | PL324091A1 (en) |
SI (1) | SI9520118A (en) |
SK (1) | SK51297A3 (en) |
WO (1) | WO1996012737A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
CA2247009C (en) | 1996-03-21 | 2009-08-04 | Imperial College Of Science, Technology And Medicine | Cryptic peptides and method for their identification |
EP0939826A2 (en) * | 1996-08-15 | 1999-09-08 | Agrivax Incorporated | Delivery of tolerogenic antigens via edible plants or plant-derived products |
CA2494338C (en) * | 1997-04-04 | 2007-07-17 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
SE9703287D0 (en) * | 1997-09-11 | 1997-09-11 | Astra Ab | Peptides |
CN1308671A (en) * | 1998-05-05 | 2001-08-15 | 科里克萨公司 | Myelin basic protein peptides and uses thereof |
US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
WO1999060021A2 (en) * | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
EP1288226A1 (en) * | 2001-09-03 | 2003-03-05 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system |
GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
DE60327618D1 (en) | 2002-03-27 | 2009-06-25 | Aegera Therapeutics Inc | ANTISENSE NUCLEOBASIS AND ITS APPLICATIONS AGAINST IAP |
DE10230381A1 (en) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
US8815794B2 (en) * | 2008-08-28 | 2014-08-26 | The Research Foundation For The State University Of New York | Treatment of amyloidoses using myelin basic protein and fragments thereof |
EP3348275A3 (en) * | 2009-03-31 | 2018-10-24 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
EA024832B1 (en) | 2009-10-12 | 2016-10-31 | ЛАЙФБИО ЛАБОРАТОРИС ЭлЭлСи | Oligopeptide binding anti mbp hydrolyzing auto antibodies, compositions and method of treating multiple sclerosis |
RU2448685C2 (en) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis |
CA2830772C (en) | 2011-03-21 | 2020-04-28 | Atlantic Cancer Research Institute | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy |
EP3094341B1 (en) | 2014-01-13 | 2019-10-02 | Berg LLC | Enolase 1 (eno1) compositions and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2512796B2 (en) * | 1987-06-24 | 1996-07-03 | オートイミュン・インコーポレイテッド | Treatment of autoimmune disease by oral administration of self-antigen |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
DK0506785T3 (en) * | 1989-12-20 | 2000-07-24 | Autoimmune Inc | Improved treatment of autoimmune diseases by aerosol administration of autoantigens |
EP0782859A1 (en) * | 1990-03-02 | 1997-07-09 | Autoimmune, Inc. | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens |
IL165071A (en) * | 1990-03-30 | 2008-06-05 | Autoimmune Inc | Peptide capable of stimulating a subgroup of t-cells from multiple sclerosis patients |
CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
EP0661996A4 (en) * | 1991-11-19 | 1997-05-21 | Anergen Inc | Mhc subunit conjugates useful in ameliorating deleterious immune responses. |
BR9306042A (en) * | 1992-02-28 | 1997-11-18 | Autoimmune Inc | Method to treat an autoimmune disease in a mammal and oral and inhalable pharmaceutical dosage forms |
IL105153A (en) * | 1992-03-25 | 1999-12-22 | Immulogic Pharma Corp | Therapeutic compositions comprising peptides derived from human t cell reactive feline protein |
DE69320967T2 (en) * | 1992-04-09 | 1999-05-12 | Autoimmune Inc | SUPPRESSION OF T-CELL PROLIFERATION BY MEANS OF PEPTIDE FRAGMENTS OF THE MYELINE BASIC PROTEIN |
WO1993025661A1 (en) * | 1992-06-10 | 1993-12-23 | President And Fellows Of Harvard College | Heterogeneous proteolipid peptide 139-151-specific t cell clones |
WO1994004121A1 (en) * | 1992-08-17 | 1994-03-03 | Autoimmune, Inc. | Bystander suppression of retroviral-associated neurological disease |
NZ273813A (en) * | 1993-09-03 | 1998-05-27 | Immulogic Pharma Corp | Myelin oligodendrocyte glycoprotein autoantigen |
WO1995007096A1 (en) * | 1993-09-06 | 1995-03-16 | La Trobe University | Treatment of autoimmune disease |
CA2172512A1 (en) * | 1993-09-22 | 1995-03-30 | Lawrence Steinman | Interaction of t-cell receptors and antigen in autoimmune disease |
AU686797B2 (en) * | 1994-04-08 | 1998-02-12 | Brigham And Women's Hospital | Treatment of autoimmune disease using oral tolerization and/or type I interferon |
WO1995027500A1 (en) * | 1994-04-08 | 1995-10-19 | Brigham And Women's Hospital | TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES |
JPH10500109A (en) * | 1994-05-10 | 1998-01-06 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | Compositions and methods of treatment for multiple sclerosis |
JP3558347B2 (en) * | 1994-06-09 | 2004-08-25 | ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー | Alpha B crystallin for use in the diagnosis and treatment of autoimmune diseases, especially multiple sclerosis |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
CA2205532A1 (en) * | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
-
1995
- 1995-10-25 EP EP95941330A patent/EP0787147A1/en not_active Withdrawn
- 1995-10-25 BR BR9509438A patent/BR9509438A/en unknown
- 1995-10-25 SK SK512-97A patent/SK51297A3/en unknown
- 1995-10-25 WO PCT/US1995/013682 patent/WO1996012737A2/en not_active Application Discontinuation
- 1995-10-25 SI SI9520118A patent/SI9520118A/en unknown
- 1995-10-25 HU HU9701843A patent/HUT77047A/en unknown
- 1995-10-25 CZ CZ971226A patent/CZ122697A3/en unknown
- 1995-10-25 PL PL95324091A patent/PL324091A1/en unknown
- 1995-10-25 CA CA002203629A patent/CA2203629A1/en not_active Abandoned
- 1995-10-25 AU AU42782/96A patent/AU4278296A/en not_active Abandoned
- 1995-10-25 IL IL11576695A patent/IL115766A0/en unknown
- 1995-10-25 JP JP8514109A patent/JPH10504039A/en active Pending
-
1997
- 1997-04-17 IS IS4466A patent/IS4466A/en unknown
- 1997-04-24 FI FI971750A patent/FI971750A/en unknown
- 1997-04-24 NO NO971900A patent/NO971900L/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUT77047A (en) | 1998-03-02 |
IS4466A (en) | 1997-04-17 |
NO971900D0 (en) | 1997-04-24 |
BR9509438A (en) | 1997-12-23 |
SK51297A3 (en) | 1998-03-04 |
FI971750A0 (en) | 1997-04-24 |
NO971900L (en) | 1997-06-25 |
CZ122697A3 (en) | 1997-09-17 |
JPH10504039A (en) | 1998-04-14 |
WO1996012737A3 (en) | 1996-10-10 |
AU4278296A (en) | 1996-05-15 |
WO1996012737A2 (en) | 1996-05-02 |
FI971750A (en) | 1997-06-24 |
IL115766A0 (en) | 1996-01-19 |
EP0787147A1 (en) | 1997-08-06 |
SI9520118A (en) | 1998-08-31 |
CA2203629A1 (en) | 1996-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL324091A1 (en) | Compositions and procedure for treating sclerosis multiplex | |
GB9422571D0 (en) | Haemorrihoidal compositions and method of use | |
IL129138A0 (en) | Methods and compositions for immunomodulation | |
IL127446A0 (en) | Compositions and methods for coating medical devices | |
EP0874828A4 (en) | Composition for treating pain | |
GB9415421D0 (en) | Cosmetic compositions and processes for manufacture thereof | |
EP0703282A3 (en) | Composition for surface treatment | |
PL317197A1 (en) | Compositions for and method of treating sclerosis multiplex | |
ZA9510792B (en) | Polymerization compounds and compositions | |
GB9624501D0 (en) | Insecticial compositions and method | |
IL111554A0 (en) | Methods and compositions for hair treatment | |
GB9405229D0 (en) | Compositions of matter | |
GB9415420D0 (en) | Cosmetic compositions and processes for manufacture thereof | |
IL112564A0 (en) | 1-beta-methyl-carbapenems and compositions containing them | |
EP0835092A4 (en) | Composition and treatment for baldness | |
HU9701150D0 (en) | Composition for preventing and treating disturbances of vision | |
IL124419A0 (en) | Composition for treating pain | |
GB9508546D0 (en) | Method and composition | |
PL314588A1 (en) | Application of pentoxyphyline in treatment of sclerosis multiplex | |
GB9419087D0 (en) | Method and composition | |
GB9414888D0 (en) | Method and composition | |
IL113444A0 (en) | Compositions and methods for treating leukemia | |
GB9416340D0 (en) | Oil treatment and compositions therefor | |
ZA953730B (en) | Compositions and treatment for multiple sclerosis | |
ZA959033B (en) | Composition and treatment for multiple sclerosis |